Athersys , Inc. (NASDAQ: ATHX ) Q2 2014 Earnings Conference Call ..... would like to welcome everyone to the Athersys ' second quarter 2014 earnings call ..... Lisa Wilson, Investor Relations for Athersys , you may begin your conference
Athersys ( ATHX +6.5% ) Q2 results : Revenues: $388K (-32.0%); Operating Loss: ($7.3M) (-18.0%); Net Income: $675K (+111.4%); EPS: $0.01 (+90.9%); Quick Assets: $38.8M (+21.3%). No financial guidance given. Post your comment!
The following audio is from a conference call that will begin on August 11, 2014 at 16:30 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now If you would like to view a transcript of this call, please click here. Complete Story »
AMBC , ATHX , BDE , CALL , CVG , CYNI , CZR , FTEK , FXEN , GALE , GCAP , GERN , GNMK , HALO , HTHT , ICEL , ICUI , IPAR , MM , MR , MTZ , NIHD , NOR , NUAN , ONTY , OPK , PDLI , RAX , REN , SKH , SUPN , TCRD , UNTD , VTR Post your comment!
We are no longer providing equity research on Athersys ATHX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
estimate intact after reviewing Athersys ' ATHX third-quarter results, a business ..... and financing arrangements. Athersys turned in a net loss of $2.3 ..... sheet. To buoy its cash balance, Athersys has entered into an equity purchase
development of Athersys ' anti-obesity candidate ATHX -105 was put ..... of obesity drug ATHX -105 following ..... clinical risk, Athersys ' MultiStem is ..... company. Although Athersys ' stem cell technology ..... performance of ATHX -105 illustrate
We are putting Athersys ATHX under review in the wake of the company's plummeting share price. Athersys is a development-stage biotech with minimal revenue and negative profits, and equity issuances are key to the firm's survival as it burns
We are maintaining our fair value estimate for Athersys ATHX after reviewing the company's progress over the past ..... MultiStem's assigned probability of approval. In May, Athersys announced positive interim results from an ongoing Phase
Athersys ATHX continues to advance its flagship stem ..... unknown about its safety and effectiveness. Athersys has completed enrollment of its Phase ..... and severity of the disease, for which Athersys received orphan drug designation for MultiStem